Table 3.

Patient-specific clinical factors associated with progression-free survival in the BRCA1/2 mutation-positive group (N = 42).

Variable	N	No. of events	(%)	Univariable analysis		Multivariable analysis
				Crude HR (95% CI)	P-value	Adjusted HR (95% CI)	P-value
PFI
≥ 12 months	20	9	45.0	0.35 (0.11–0.94)	0.048	0.32 (0.10–0.86)	0.033
< 12 months	22	9	40.9	1		1
Response to the last platinum dose according to RECIST
Complete	7	3	42.9	2.15 (0.49–6.78)	0.239
Partial	35	15	42.9	1
CA-125 level within reference values after the last platinum dose
≤ 35 U/mL	34	14	41.2	0.51 (0.18–1.82)	0.243
> 35 U/mL	8	4	50.0	1
Age
≥ 60 years	15	7	46.7	1.10 (0.42–2.80)	0.839
< 60 years	27	11	40.7	1
NLR
≥ 3.32	6	2	33.3	1.63 (0.37–5.02)	0.444
< 3.32	36	16	44.4	1
PLR
≥ 210	12	8	66.7	2.52 (0.87–6.53)	0.066	2.35 (0.80–6.27)	0.096
< 210	30	10	33.3	1		1

BRCA breast cancer susceptibility gene, HR hazard ratio, CI confidence interval, PFI platinum-free interval, RECIST Response Evaluation Criteria in Solid Tumors, CA-125 cancer antigen 125, NLR neutrophil-to-lymphocyte ratio, PLR platelet-to-lymphocyte ratio.